on the surface of cancer cells, and which can thereby mediate T-cell activation, simulation of an immune response and killing of cancer cells that express B7-H3. It is an object of this invention to identify such compositions and treatment regimens.

Summary:

[0021] The present disclosure is directed to combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 (*i.e.*, a B7-H3-binding molecule) and a second molecule that that specifically binds to human PD-1 (*i.e.*, a PD-1-binding molecule) to a subject for the treatment of cancer and inflammation. The disclosure also concerns pharmaceutical compositions that comprise a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 that are capable of mediating, and more preferably enhancing, the activation of the immune system against cancer cells that are associated with a variety of human cancers. The disclosure also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.

[0021a] In one aspect, there is provided use of an anti-B7-H3 antibody or antigen-binding fragment thereof in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 1-15 mg/kg body weight and in combination with an anti-PD-1 antibody or antigen-binding fragment thereof.

[0022] The disclosure also provides a method of treating a cancer comprising administering to a subject in need thereof, a molecule that specifically binds to B7-H3, and a molecule that specifically binds to PD-1.

[0023] The disclosure particularly concerns examples of such uses and methods, wherein the molecule that specifically binds to B7-H3 is an anti-B7-H3 antibody or antigen-binding fragment thereof, and the molecule that specifically binds to PD-1 is an anti-PD-1 antibody, or an antigen-binding fragment thereof.

[0024] The disclosure particularly concerns the example of such uses and methods wherein the anti-B7-H3 antibody, or antigen-binding fragment thereof:

(a) competes for B7-H3 binding with BRCA84D, BRCA69D, PRCA157, or with an anti-B7-H3 antibody selected from **Table 5**; or

(b) has the three heavy chain CDRs and the three light chain CDRs of BRCA84D, hBRCA84D (1.1), hBRCA84D (2.2), hBRCA84D-2, hBRCA69D (1.1), hBRCA (2.2), or the three heavy chain CDRs and the three light chain CDRs of an anti-B7-H3 selected from **Table 5**; or

(c) has the heavy chain variable domain and the light chain variable domain of BRCA84D, hBRCA84D (1.1), hBRCA84D (2.2), hBRCA84D-2, hBRCA69D (1.1), hBRCA (2.2), or the heavy chain variable domain

and the light chain variable domain of an anti-B7-H3 selected from **Table 5**.

[0025] The disclosure particularly concerns the example of such uses and methods wherein the anti-PD-1 antibody, or antigen-binding fragment thereof:

(a) competes for PD-1 binding with nivolumab, pembrolizumab, pidilizumab, PD-1 mAb 3, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb7, PD-1 mAb 8, or with an anti-PD-1 antibody selected from **Table 6**; or

(b) has the three heavy chain CDRs and the three light chain CDRs of nivolumab, pembrolizumab, pidilizumab, PD-1 mAb 3, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb7, PD-1 mAb 8, or the three heavy chain CDRs and the three light chain CDRs of an anti-PD-1 antibody selected from **Table 6**; or

(c) has the heavy chain variable domain and the light chain variable domain of nivolumab, pembrolizumab, pidilizumab, PD-1 mAb 3, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb7, PD-1 mAb 8, or the heavy chain variable domain and the light chain variable domain of an anti-PD-1 antibody selected from **Table 6**.

[0026] The disclosure further concerns examples of such uses and methods wherein the anti-B7-H3 antibody, or antigen-binding fragment thereof, comprises an Fc Domain, and/or the anti-PD-1 antibody, or antigen-binding fragment thereof, comprises an Fc Domain. The disclosure further concerns the examples of such uses and methods wherein the anti-B7-H3 antibody or antigen-binding fragment thereof, comprises a variant Fc Domain having one, two, three, four, five or more modifications in the Fc Domain that enhances ADCC. The disclosure further concerns the examples of such uses and methods wherein the Fc Domain modifications that enhance(s) ADCC comprise any one, any two, any three, any four, or all five of the substitutions L235V, F243L, R292P, Y300L and P396L. The disclosure further concerns the examples of such uses and methods wherein the anti-PD-1 antibody or antigen-binding fragment thereof, comprises: (a) a variant Fc Domain having at least one modification in the Fc Domain that reduces or abolishes ADCC activity; or (b) an IgG4 Fc Domain. The disclosure further concerns the examples of such uses and methods wherein the Fc Domain modifications that reduce or abolish ADCC comprise the substitution of L234A; L235A; or L234A and L235A, preferably of an IgG1 Fc Domain.

[0027] The disclosure further concerns examples of such uses and methods, wherein the anti-B7-H3 antibody is hBRCA84D-2 and the anti-PD-1 antibody is nivolumab, pembrolizumab, pidilizumab, or PD-1 mAb 6-ISQ. The disclosure further concerns examples of such uses and methods, wherein the anti-B7-H3 antibody is hBRCA84D-2 and the anti-PD-1 antibody, or antigen-binding fragment thereof comprises the VH and VL of nivolumab, pembrolizumab, pidilizumab, PD-1 mAb 3, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, or an anti-PD-1 antibody selected from **Table 6**.

[0028] The disclosure additionally concerns examples of such uses and methods wherein the molecule that specifically binds to B7-H3 (particularly an anti-B7-H3 antibody) is administered at a dosage of 1-15 mg/kg body weight every week and the molecule that specifically binds to PD-1 (particularly an anti-PD-1 antibody) is administered at a fixed dosage of 200 mg every three weeks. The disclosure also concerns examples of such uses and methods wherein the molecule that specifically binds to B7-H3 (particularly an anti-B7-H3 antibody) is administered at a dosage of 1-15 mg/kg body weight every week and the molecule that specifically binds to PD-1 (particularly an anti-PD-1 antibody) is administered at a dosage of 1-10 mg/kg body weight every two or three weeks. The disclosure further concerns examples of such uses and methods wherein the molecule that specifically binds to B7-H3 (particularly an anti-B7-H3 antibody) is administered at a dosage of selected from 1 mg/kg, 3 mg/kg, 10 mg/kg and 15 mg/kg body weight every week and the molecule that specifically binds to PD-1 (particularly an anti-PD-1 antibody) is administered at a fixed dosage of 200 mg every three weeks. The disclosure further concerns examples of such uses and methods wherein the molecule that specifically binds to B7-H3 (particularly an anti-B7-H3 antibody) is administered at a dosage of selected from 1 mg/kg, 3 mg/kg, 10 mg/kg and 15 mg/kg body weight every week and the molecule that specifically binds to PD-1 (particularly an anti-PD-1 antibody) is administered at a dosage of selected from 1 mg/kg, 2 mg/kg, 3 mg/kg and 10 mg/kg body weight every two or three weeks. The disclosure particularly concerns examples of such uses and methods wherein the molecule that specifically binds to B7-H3 (particularly an anti-B7-H3 antibody) is administered at a dosage of selected from 3 mg/kg, 10 mg/kg and 15 mg/kg body weight every week and the molecule that specifically binds to PD-1 (particularly an anti-PD-1 antibody) is administered at a dosage of 2 mg/kg body weight every three weeks. The disclosure particularly concerns examples of such uses and methods wherein the molecule that specifically binds to B7-H3 (particularly an anti-B7-H3 antibody) is administered at a dosage of selected from 3 mg/kg, 10 mg/kg and 15 mg/kg body weight every week and the molecule that specifically binds to PD-1 (particularly an anti-

PD-1 antibody) is administered at a dosage of 3 mg/kg body weight every two weeks. The disclosure further concerns examples of such uses and methods wherein the molecule that specifically binds to B7-H3 (particularly an anti-B7-H3 antibody) and the molecule that specifically binds to PD-1 (particularly an anti-PD-1 antibody) are administered by IV infusion. The disclosure also concerns examples of such uses and methods wherein every two or three weeks the molecule that specifically binds to B7-H3 (particularly an anti-B7-H3 antibody) and the molecule that specifically binds to PD-1 (particularly an anti-PD-1 antibody) are administered with a 48-hour period.

[0029] The disclosure particularly concerns examples of such uses and methods wherein the cancer is a cancer in which B7-H3 is expressed. The disclosure further concerns examples of such uses and methods wherein the cancer is a squamous cell cancer of the head and neck (SCCHN), a bladder cancer, a breast cancer, a colorectal cancer, a gastric cancer, a glioblastoma, a kidney cancer, a lung cancer, a melanoma, an ovarian cancer, a pancreatic cancer, a pharyngeal cancer, a prostate cancer, a renal cell carcinoma, a small round blue cell tumor, a neuroblastoma, or a rhabdomyosarcoma, in which B7-H3 is expressed.

[0030] The disclosure additionally concerns examples of such uses and methods further comprising the step of administering a third therapeutic agent, particularly wherein the third therapeutic agent is an anti-angiogenic agent, an anti-neoplastic agent, a chemotherapeutic agent, or a cytotoxic agent

Detailed Description of the Invention:

[0031] The present invention is directed to a combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 and a second molecule that that specifically binds to human PD-1 to a subject for the treatment of cancer and/or inflammation. The invention also concerns pharmaceutical compositions that comprise a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 that are capable of mediating, and more preferably enhancing, the activation of the immune system against cancer cells that are associated with any of a variety of human cancers. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases in recipient subjects.

What Is Claimed Is:

Claim 1. Use of an anti-B7-H3 antibody or antigen-binding fragment thereof in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 1-15 mg/kg body weight and in combination with an anti-PD-1 antibody or antigen-binding fragment thereof.

Claim 2. The use of claim 1, wherein said anti-B7-H3 antibody, or antigen-binding fragment thereof:

(a) competes for B7-H3 binding with an anti-B7-H3 antibody:

(1) comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:20 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 19; or

(2) comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:32 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:31; or

(3) comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:37; or

(4) selected from the group consisting of: LUCA1; BLA8; PA20; SKIN2; M30; cM30; M30-H1-L1; M30-H1-L2; M30-H1-L3; M30-H1-L4; M30-H1-L5; M30-H1-L6; M30-H1-L7; M30-H4-L1; M30-H4-L2; M30-H4-L3; M30-H4-L4; and 8H9; or

(b) comprises:

(1) the three heavy chain CDRs of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:20, and the three light chain CDRs of a light chain variable domain comprising the amino acid sequence of SEQ ID NO:19; or

(2) the three heavy chain CDRs of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:32 or 36,

and the three light chain CDRs of a light chain variable domain comprising the amino acid sequence of SEQ ID NO:31 or 34; or

(3) the three heavy chain CDRs of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:38, and the three light chain CDRs of a light chain variable domain comprising the amino acid sequence of SEQ ID NO:37; or

(4) the three heavy chain CDRs and the three light chain CDRs of an anti-B7-H3 antibody selected from the group consisting of: LUCA1; BLA8; PA20; SKIN2; M30; cM30; M30-H1-L1; M30-H1-L2; M30-H1-L3; M30-H1-L4; M30-H1-L5; M30-H1-L6; M30-H1-L7; M30-H4-L1; M30-H4-L2; M30-H4-L3; M30-H4-L4; and 8H9; or

(c) comprises:

(1) a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:20, 27, 28, 29 and 30, and a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 22, 23, 24, 25 and 26; or

(2) a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:32, 35 and 36, and a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:31, 33 and 34; or

(3) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:38, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:37; or

(4) a heavy chain variable domain and a light chain variable domain of an anti-B7-H3 antibody selected from the group consisting of: LUCA1; BLA8; PA20; SKIN2; M30; cM30; M30-H1-L1; M30-H1-L2; M30-H1-L3; M30-H1-L4; M30-H1-L5; M30-H1-L6; M30-H1-L7; M30-H4-L1; M30-H4-L2; M30-H4-L3; M30-H4-L4; and 8H9.

Claim 3. The use of any one of claims 1-2, wherein said anti-PD-1 antibody, or antigen-binding fragment thereof:

(a) competes for PD-1 binding with an anti-PD-1 antibody:

(1) selected from the group consisting of: nivolumab, pembrolizumab, pidilizumab, PD1-17; PD1-28; PD1-33; PD1-35; PD1-F2; 17D8; 2D3; 4H1; 5C4; 4A11; 7D3; 5F4; hPD-1.08A; hPD-1.09A; 109A; K09A; 409A; h409A11; h409A16; h409A17; Codon optimized 109A; Codon optimized 409A; 1E3; 1E8; 1H3; 9A2; 10B11; 6E9; APE1922; APE1923; APE1924; APE1950; APE1963; APE2058; GA1; GA2; GB1; GB6; GH1; A2; C7; H7; SH-A4; SH-A9; RG1H10; RG1H11; RG2H7; RG2H10; RG3E12; RG4A6; RG5D9; RG1H10-H2A-22-1S; RG1H10-H2A-27-2S; RG1H10-3C; RG1H10-16C; RG1H10-17C; RG1H10-19C; RG1H10-21C; RG1H10-23C2; H1M7789N; H1M7799N; H1M7800N; H2M7780N; H2M7788N; H2M7790N; H2M7791N; H2M7794N; H2M7795N; H2M7796N; H2M7798N; H4H9019P; H4xH9034P2; H4xH9035P2; H4xH9037P2; H4xH9045P2; H4xH9048P2; H4H9057P2; H4H9068P2; H4xH9119P2; H4xH9120P2; H4Xh9128p2; H4Xh9135p2; H4Xh9145p2; H4Xh8992p; H4Xh8999p; and H4Xh9008p; or

(2) comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:46, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:47; or

(3) comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:50, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:51; or

(4) comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:52, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:53; or

(5) comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:54, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:55; or

(6) comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:56, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:57; or

(b) comprises:

(1) the three heavy chain CDRs and the three light chain CDRs of an anti-PD-1 antibody selected from the group consisting of: nivolumab, pembrolizumab, pidilizumab, PD1-17; PD1-28; PD1-33; PD1-35; PD1-F2; 17D8; 2D3; 4H1; 5C4; 4A11; 7D3; 5F4; hPD-1.08A; hPD-1.09A; 109A; K09A; 409A; h409A11; h409A16; h409A17; Codon optimized 109A; Codon optimized 409A; 1E3; 1E8; 1H3; 9A2; 10B11; 6E9; APE1922; APE1923; APE1924; APE1950; APE1963; APE2058; GA1; GA2; GB1; GB6; GH1; A2; C7; H7; SH-A4; SH-A9; RG1H10; RG1H11; RG2H7; RG2H10; RG3E12; RG4A6; RG5D9; RG1H10-H2A-22-1S; RG1H10-H2A-27-2S; RG1H10-3C; RG1H10-16C; RG1H10-17C; RG1H10-19C; RG1H10-21C; RG1H10-23C2; H1M7789N; H1M7799N; H1M7800N; H2M7780N; H2M7788N; H2M7790N; H2M7791N; H2M7794N; H2M7795N; H2M7796N; H2M7798N; H4H9019P; H4xH9034P2; H4xH9035P2; H4xH9037P2; H4xH9045P2; H4xH9048P2; H4H9057P2; H4H9068P2; H4xH9119P2; H4xH9120P2; H4Xh9128p2; H4Xh9135p2; H4Xh9145p2; H4Xh8992p; H4Xh8999p; and H4Xh9008p; or

(2) the three heavy chain CDRs of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:46, and the three light chain CDRs of a light chain variable domain comprising the amino acid sequence of SEQ ID NO:47; or

(3) the three heavy chain CDRs of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:50, and the

three heavy chain CDRs of a light chain variable domain comprising the amino acid sequence of SEQ ID NO:51; or

(4) the three heavy chain CDRs of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:52, and the three heavy chain CDRs of a light chain variable domain comprising the amino acid sequence of SEQ ID NO:53; or

(5) the three heavy chain CDRs of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:54, and the three heavy chain CDRs of a light chain variable domain comprising the amino acid sequence of SEQ ID NO:55; or

(6) the three heavy chain CDRs of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:56, and the three heavy chain CDRs of a light chain variable domain comprising the amino acid sequence of SEQ ID NO:57; or

(c) comprises:

(1) the heavy chain variable domain and the light chain variable domain of an anti-PD-1 antibody selected from the group consisting of: nivolumab, pembrolizumab, pidilizumab, PD1-17; PD1-28; PD1-33; PD1-35; PD1-F2; 17D8; 2D3; 4H1; 5C4; 4A11; 7D3; 5F4; hPD-1.08A; hPD-1.09A; 109A; K09A; 409A; h409A11; h409A16; h409A17; Codon optimized 109A; Codon optimized 409A; 1E3; 1E8; 1H3; 9A2; 10B11; 6E9; APE1922; APE1923; APE1924; APE1950; APE1963; APE2058; GA1; GA2; GB1; GB6; GH1; A2; C7; H7; SH-A4; SH-A9; RG1H10; RG1H11; RG2H7; RG2H10; RG3E12; RG4A6; RG5D9; RG1H10-H2A-22-1S; RG1H10-H2A-27-2S; RG1H10-3C; RG1H10-16C; RG1H10-17C; RG1H10-19C; RG1H10-21C; RG1H10-23C2; H1M7789N; H1M7799N; H1M7800N; H2M7780N; H2M7788N; H2M7790N; H2M7791N; H2M7794N; H2M7795N; H2M7796N; H2M7798N; H4H9019P; H4xH9034P2; H4xH9035P2; H4xH9037P2; H4xH9045P2; H4xH9048P2; H4H9057P2; H4H9068P2; H4xH9119P2; H4xH9120P2; H4Xh9128p2; H4Xh9135p2; H4Xh9145p2; H4Xh8992p; H4Xh8999p; and H4Xh9008p; or

(2) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:46, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:47; or

(3) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:50, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:51; or

(4) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:52, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:53; or

(5) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:54, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:55; or

(6) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:56, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:57.

Claim 4. The use of any one of claims 1-3, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof comprises an Fc Domain, and said anti-PD-1 antibody or antigen-binding fragment thereof comprises an Fc Domain.

Claim 5. The use of claim 4, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof, comprises a variant Fc Domain having at least one modification in the Fc Domain that enhances ADCC.

Claim 6. The use of claim 4 or claim 5, wherein said anti-PD-1 antibody or antigen-binding fragment thereof, comprises:

(a) a variant Fc Domain having at least one modification in the Fc Domain that reduces or abolishes ADCC activity; or

(b) an IgG4 Fc Domain.

Claim 7. The use of any one of claims 1-6, wherein said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a fixed dosage of between 50 mg and 500 mg.

Claim 8. The use of claim 7, wherein said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a fixed dosage of 300 mg.

Claim 9. The use of claim 7, wherein said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a fixed dosage of 200 mg.

Claim 10. The use of any one of claims 1-6, wherein said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 1-10 mg/kg body weight.

Claim 11. The use of any one of claims 1-10, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 1 mg/kg body weight, about 3 mg/kg body weight, about 10 mg/kg body weight or about 15 mg/kg body weight.

Claim 12. The use of claim 11, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered at a dosage of 15 mg/kg body weight.

Claim 13. The use of claim 10, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 1 mg/kg body weight, about 3 mg/kg body weight, about 10 mg/kg body weight or about 15 mg/kg body weight, and said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 1 mg/kg body weight, about 2 mg/kg body weight, about 3 mg/kg body weight, about 5 mg/kg body weight, about 6 mg/kg body weight, or about 10 mg/kg body weight.

Claim 14. The use of claim 13, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 3 mg/kg body weight, about 10 mg/kg body weight, or about 15 mg/kg body weight, and said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 5 mg/kg body weight.

Claim 15. The use of claim 13, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 3 mg/kg body weight, about 10 mg/kg body weight, or about 15 mg/kg body weight, and said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 6 mg/kg body weight.

Claim 16. The use of claim 13, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 3 mg/kg body weight, about 10 mg/kg body weight, or about 15 mg/kg body weight, and said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 10 mg/kg body weight.

Claim 17. The use of any one of claims 1-16, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered every week.

Claim 18. The use of any one of claims 1-16, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered every three weeks.

Claim 19. The use of any one of claims 1-18, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is to be administered every two weeks.

Claim 20. The use of any one of claims 1-18, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is to be administered every three weeks.

Claim 21. The use of any one of claims 1-6, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 15 mg/kg body weight every three weeks, and said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a fixed dosage of between 50 mg and 500 mg every three weeks.

Claim 22. The use of claim 21, wherein said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a fixed dosage of 300 mg every three weeks.

Claim 23. The use of claim 21, wherein said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a fixed dosage of 200 mg every three weeks.

Claim 24. The use of any one of claims 1-6, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 15 mg/kg body weight every three weeks and said anti-PD-1 antibody or antigen-binding fragment thereof is to be administered at a dosage of about 5 mg/kg body weight every three weeks.

Claim 25. The use of any one of claims 1-24, wherein the anti-B7-H3 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are to be administered by IV infusion.

Claim 26. The use of any one of claims 1-16, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof and said anti-PD-1 antibody or antigen-binding fragment thereof are to be administered every three weeks and within a 48-hour period of each other.

Claim 27. The use of any one of claims 1-16, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof and said anti-PD-1 antibody or antigen-binding fragment thereof are to be administered every two weeks and within a 48-hour period of each other.

Claim 28. The use of any one of claims 1-27, wherein said cancer is a B7-H3-expressing cancer.

Claim 29. The use of claim 28, wherein said B7-H3-expressing cancer is selected from the group consisting of: a squamous cell cancer of the head and neck (SCCHN), a bladder cancer, a breast cancer, a colorectal cancer, a gastric cancer, a glioblastoma, a kidney cancer, a lung cancer, a melanoma, an ovarian cancer, a pancreatic cancer, a pharyngeal cancer, a prostate cancer, a renal cell carcinoma, a small round blue cell tumor, a neuroblastoma, and a rhabdomyosarcoma.

Claim 30. The use of claim 29, wherein said B7-H3-expressing cancer is a squamous cell cancer of the head and neck (SCCHN).

Claim 31. The use of any one of claims 1-30, wherein said anti-B7-H3 antibody or antigen-binding fragment thereof and said anti-PD-1 antibody or antigen-binding fragment thereof are to be administered in further combination with a third therapeutic agent selected from the group consisting of an anti-angiogenic agent, an anti-neoplastic agent, a chemotherapeutic agent, and a cytotoxic agent.

Claim 32. The use of any one of claims 1-31, wherein said anti-B7-H3 antibody comprises a light chain comprising the amino acid sequence of SEQ ID

NO:39, and a heavy chain comprising the amino acid sequence of SEQ ID NO:40.

Claim 33. The use of any one of claims 1-32, wherein said anti-PD-1 antibody is pembrolizumab.

Claim 34. The use of any one of claims 1-32, wherein said anti-PD-1 antibody is nivolumab.

Claim 35. The use of any one of claims 1-32, wherein said anti-PD-1 antibody is pidilizumab.

Claim 36. The use of any one of claims 1-32, wherein said anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:46 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:47.

Claim 37. The use of any one of claims 1-32, wherein said anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:50 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:51.

Claim 38. The use of any one of claims 1-32, wherein said anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:52 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:53.

Claim 39. The use of claim 38, wherein said anti-PD-1 antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:58 and a heavy chain comprising the amino acid sequence of SEQ ID NO:59.

Claim 40. The use of any one of claims 1-32, wherein said anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:54 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:55.

Claim 41. The use of any one of claims 1-32, wherein said anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:56 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:57.

Claim 42. The use of any one of claims 1-32, wherein said anti-PD-1 antibody is selected from the group consisting of: PD1-17; PD1-28; PD1-33; PD1-35; PD1-F2; 17D8; 2D3; 4H1; 5C4; 4A11; 7D3; 5F4; hPD-1.08A; hPD-1.09A; 109A; K09A; 409A; h409A11; h409A16; h409A17; Codon optimized 109A; Codon optimized 409A; 1E3; 1E8; 1H3; 9A2; 10B11; 6E9; APE1922; APE1923; APE1924; APE1950; APE1963; APE2058; GA1; GA2; GB1; GB6; GH1; A2; C7; H7; SH-A4; SH-A9; RG1H10; RG1H11; RG2H7; RG2H10; RG3E12; RG4A6; RG5D9; RG1H10-H2A-22-1S; RG1H10-H2A-27-2S; RG1H10-3C; RG1H10-16C; RG1H10-17C; RG1H10-19C; RG1H10-21C; RG1H10-23C2; H1M7789N; H1M7799N; H1M7800N; H2M7780N; H2M7788N; H2M7790N; H2M7791N; H2M7794N; H2M7795N; H2M7796N; H2M7798N; H4H9019P; H4xH9034P2; H4xH9035P2; H4xH9037P2; H4xH9045P2; H4xH9048P2; H4H9057P2; H4H9068P2; H4xH9119P2; H4xH9120P2; H4Xh9128p2; H4Xh9135p2; H4Xh9145p2; H4Xh8992p; H4Xh8999p; and H4Xh9008p.